Human Anaplasmosis in Eastern France

August 29, 2011 updated by: University Hospital, Strasbourg, France

Epidemiology and Clinical Presentation of Human Anaplasmosis in Eastern France

Anaplasmosis is a tick-borne transmitted infection. Its clinical expression include fever, cytopenia and hepatitis.This infection was initially described in United States. In Europe, its epidemiology is not well known. Some isolated cases have been diagnosed in several country, were the tick Ixodes ricinus is known to transmitted another infection :the Lyme borreliosis.The purpose of our study is to look systematically for Anaplasmosis, in patient living in Eastern France, and presenting with compatible clinical symptoms using a new diagnosis tool : PCR in blood samples. So we will have new data about epidemiology in our country and the clinical symptoms that are associated with Anaplasmosis.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • France
      • Besançon, France
        • Not yet recruiting
        • Service des Maladies Infectieuses et Tropicales - CHU de Besançon
        • Contact:
        • Principal Investigator:
          • BRUNO HOEN, MD
      • Colmar, France
        • Recruiting
        • Centre Hospitalier de Colmar
        • Contact:
        • Principal Investigator:
          • Martin MARTINOT, MD
        • Sub-Investigator:
          • MAHSA MOHSENI, MD
      • Dijon, France
        • Not yet recruiting
        • Département d'Infectiologie CHU de Dijon
        • Contact:
      • Guebwiller, France
        • Recruiting
        • Centre Hospitalier de Guebwiller
        • Contact:
        • Principal Investigator:
          • GENEVIEVE BOESS, MD
      • Haguenau, France
        • Recruiting
        • Centre Hospitalier de Haguenau
        • Contact:
        • Principal Investigator:
          • BERNARD WILLEMIN, MD
        • Sub-Investigator:
          • REGIS DUKIC, MD
      • Mulhouse, France
        • Recruiting
        • Centre Hospitalier de Mulhouse
        • Contact:
        • Principal Investigator:
          • JOY MOOTIEN, MD
        • Sub-Investigator:
          • PIERRE KIEFFER, MD
      • Nancy, France
        • Not yet recruiting
        • Service des Maladies Infectieuses et Tropicales - CHU de Nancy
        • Contact:
        • Principal Investigator:
          • CHRISTIAN RABAUD, MD
      • Reims, France
        • Recruiting
        • Service de Médecine Interne et Maladies Infectieuses - CHU de Reims
        • Contact:
        • Principal Investigator:
          • CHRISTOPHE STRADY, MD
      • Saverne, France
        • Recruiting
        • Centre Hospitalier de Saverne
        • Contact:
        • Principal Investigator:
          • ELISABETH WURTZ, MD
      • Strasbourg, France, 67091
        • Recruiting
        • Service des Maladies Infectieuses et Tropicales Hôpitaux Universitaires de Strasbourg
        • Contact:
        • Sub-Investigator:
          • GUILLAUME CAMUSET, MD
        • Sub-Investigator:
          • DANIEL CHRISTMANN, MD
        • Sub-Investigator:
          • Benoît JAULHAC, MD
        • Sub-Investigator:
          • Sylvie DE MARTINO, MD
      • Sélestat, France
        • Recruiting
        • Centre Hospitalier de Sélestat
        • Contact:
        • Principal Investigator:
          • FRANCOIS SAGEZ, MD
      • Wissembourg, France
        • Recruiting
        • Centre hospitalier de Wissembourg
        • Contact:
        • Principal Investigator:
          • ANDRE MICHEL, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 years and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

patients with Anaplasma phagocytophilia

Description

Inclusion Criteria:

  • patient with at least one of following symptoms : fever or muscular pain or articular pain or respiratory signs or neurological signs or meningitis or erythema occurring during the three weeks after a tick bite-
  • Or
  • patient with fever with at least one of following criteria : thrombocytopenia, leucopenia, hepatitis, without any other cause that can explain these abnormalities.
  • Or
  • patient with tick-borne encephalitis, or primary stage Lyme borreliosis

Exclusion Criteria:

  • children less that 10 years
  • pregnancy
  • patients with an other diagnosis that can explain clinical symptoms or biological abnormalities
  • antibiotherapy with cyclins during the days before inclusion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Anaplasma
Procedure: Blood sampling
  • Anaplasma diagnosis test : serology and PCR
  • If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Risk factor, clinical and biological markers of infection for patients with Anaplasma antibody seroconversion
Time Frame: 6 weeks
6 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Strasbourg, France

Investigators

  • Principal Investigator: YVES HANSMANN, MD, Service des Maladies Infectieuses et Tropicales Hôpitaux Universitaires de Strasbourg

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2009

Primary Completion (ANTICIPATED)

April 1, 2012

Study Registration Dates

First Submitted

November 10, 2009

First Submitted That Met QC Criteria

November 13, 2009

First Posted (ESTIMATE)

November 16, 2009

Study Record Updates

Last Update Posted (ESTIMATE)

August 30, 2011

Last Update Submitted That Met QC Criteria

August 29, 2011

Last Verified

August 1, 2011

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 3960

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Blood sampling

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe